Syncytiotrophoblast extracellular microvesicle profiles in maternal circulation for noninvasive diagnosis of preeclampsia

Lisa Levine1,5, Andreas Habertheuer2,5, Chirag Ram2, Laxminarayana Korutla2, Nadav Schwartz1, Robert W. Hu2, Sanjana Reddy2, Andrew Freas2, Patrick D. Zielinski2, Joey Harmon2, Sudheer Kumar Molugu3, Samuel Parry1 & Prashanth Vallabhajosyula2,4*

Preeclampsia is the most common placental pathology in pregnant females, with increased morbidity and mortality incurred on the mother and the fetus. There is a need for improved biomarkers for diagnosis and monitoring of this condition. Placental syncytiotrophoblasts at the maternal-fetal interface release nanoparticles, including extracellular microvesicles, into the maternal blood during pregnancy. Syncytiotrophoblast extracellular microvesicles (STEVs) are being studied for their diagnostic potential and for their potential physiologic role in preeclampsia. We hypothesized that STEV profiles in maternal circulation would be altered under conditions of preeclampsia compared to normal pregnancy. Extracellular vesicles (EVs) released by BeWo cells in vitro showed high expression of syncytin-1, but no plac1 expression, demonstrating that trophoblast cell EVs express syncytin-1 on their surface. Placental alkaline phosphatase also showed high expression on BeWo EVs, but due to concern for cross reactivity to highly prevalent isoforms of intestinal and bone alkaline phosphatase, we utilized syncytin-1 as a marker for STEVs. In vivo, syncytin-1 protein expression was confirmed in maternal plasma EVs from Control and Preeclampsia subjects by Western blot, and overall, lower expression was noted in samples from patients with preeclampsia (n = 8). By nanoparticle analysis, EV profiles from Control and Preeclampsia groups showed similar total plasma EV quantities (p = 0.313) and size distribution (p = 0.415), but STEV quantitative signal, marked by syncytin-1 specific EVs, was significantly decreased in the Preeclampsia group (p = 2.8 × 10−11). Receiver operating characteristic curve demonstrated that STEV signal threshold cut-off of <0.316 was 95.2% sensitive and 95.6% specific for diagnosis of preeclampsia in this cohort (area under curve = 0.975 ± 0.020). In conclusion, we report that the syncytin-1 expressing EV profiles in maternal plasma might serve as a placental tissue specific biomarker for preeclampsia.

Preeclampsia is the most common pregnancy-associated disorder, affecting up to 3 to 5% of pregnancies1–4. In addition to increased morbidity and mortality seen in the mother, preeclampsia is also associated with fetal complications, including premature birth and fetal growth restriction. Preeclampsia manifests as new onset hypertension (systolic blood pressure >140 mmHg and diastolic pressure >90 mmHg; proteinuria), which can occur at an early stage or late stage during pregnancy. Its severity can also vary and is classified as mild, moderate, severe preeclampsia, and eclampsia5–7. The precise mechanistic cause of preeclampsia is being extensively investigated, but there is wide agreement that the disorder originates in the placenta8–14, and is related to decreased uteroplacental blood flow8,11–15, which leads to a cascade of physiologic processes manifesting clinically as a pregnancy-associated hypertensive disorder16–18.

1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Pennsylvania, Pennsylvania, USA. 2Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Pennsylvania, USA. 3Department of Biochemistry and Biophysics, University of Pennsylvania, Pennsylvania, USA. 4Division of Cardiac Surgery, Department of Surgery, Yale University School of Medicine, New Haven, USA. 5These authors contributed equally: Lisa Levine and Andreas Habertheuer. *email: Prashanth.Vallabhajosyula@yale.edu
Placental trophoblasts, especially syncytiotrophoblasts, are fetal-derived cells that lie at the maternal-fetal interface and tightly regulate exchange of nutrients, metabolites, and other macromolecules between these two entities. Several studies have shown that syncytiotrophoblasts are highly active in fetal physiology, and their dysregulation has been implicated in placental pathophysiology. In addition, syncytiotrophoblasts also release a wide array of extracellular vesicles into the maternal circulation throughout gestation, with increasing amounts seen during the latter stages of pregnancy. These include apoptotic bodies, microvesicles such as ectosomes and microparticles, and extracellular microvesicles (EVs) including exosomes, which are released via different mechanistic processes and are detectable in peripheral blood as microvesicles of different sizes. Although the exact definition of these microvesicles by size remains somewhat nebulous, there is excellent consensus that exosomes are nanoparticles in the range of 30 to 150 nm that are specifically released through endosomal pathway utilizing endocytic machinery via subcellular structures called multivesicular bodies. Exosomes express canonical and tissue-specific proteins on their surface, and their intraexosomal compartments are enriched in functional macromolecules implicated to have paracrine and systemic effects on target tissues.

Recently, our group investigated the diagnostic potential of tissue-specific EV profiling as a noninvasive diagnostic tool for early detection and monitoring of immunologic rejection in transplantation. We demonstrated that injury to the transplant tissue leads to early changes in transplant tissue-specific EVs in recipient blood, and their profiles predicted early acute rejection with high accuracy in a time-sensitive manner. We translated this concept in the setting of pregnancy-associated disorders and hypothesized that placental injury/dysfunction associated with preeclampsia might lead to alterations in placental-specific EVs in maternal plasma. If so, as suggested by other groups, characterization of placenta-specific EVs might serve as a novel, diagnostic biomarker for preeclampsia. Here we report our initial investigation of this concept.

Materials and Methods

Study design and subject samples. This was a planned sub-study utilizing blood samples that were collected from women enrolled in a prospective longitudinal study evaluating biomarker differences in women with and without severe preeclampsia. Women were enrolled in this study from April 2015 to May 2017 at the Hospital of the University of Pennsylvania after obtaining written informed consent. Institutional Review Board approval was obtained prior to initiation of the study (IRB #821392). We also confirm that all experiments were performed in accordance with the relevant guidelines and regulations. Cases were women diagnosed with preterm (23–36 6/7 weeks) preeclampsia with severe features who were admitted to the Obstetrical unit at our hospital. Preeclampsia with severe features was defined by current guidelines from the Hypertension Task Force of the American College of Obstetricians and Gynecologists. Normotensive controls were recruited in the outpatient setting and matched by gestational age of preeclampsia diagnosis (±3 weeks), race, maternal age (±8 years), and body mass index (±5 kg/m2). Blood was drawn at the time of enrollment for both cases and controls. Women were followed prospectively into the postpartum period. Controls who developed any form of pregnancy-related hypertension were subsequently excluded post enrollment. All women with preexisting cardiovascular disease were excluded. Baseline patient demographics and characteristics are summarized in Table 1.

BeWo cell line and EV isolation. To validate the presence of syncytiotrophoblast-specific markers on EV surface, we first analyzed for these markers in an in vitro system. Human choriocarcinoma-derived cell line (BeWo) was grown in Dulbecco’s modified Eagle’s medium (DMEM) (with L-glutamine and 4500 mg glucose/L, without sodium bicarbonate; Sigma Chemical Co., Missouri, cat. no. D-5648), heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Georgia) and penicillin/streptomycin (10,000 U/mL; Invitrogen, California) until 90% confluent. Culture medium was replaced with Exosome-free FBS and cells were grown for another 48 hours. Culture medium was collected and EVs were isolated using methodology of ultracentrifugation. First, culture medium was spun at 800 g for 5 minutes followed by 2000 g for 10 minutes to remove cellular debris. Supernatant was collected and ultrafiltered using a 100 kDa cut-off membrane, followed by ultracentrifugation at 120,000 g for 2 hours at 4°C. Pellet containing EVs were resuspended in 1× phosphate buffered saline (PBS)

Plasma EV isolation. Blood was collected from all patients in EDTA tubes and was immediately spun down at 2,000 g for 15 minutes at 4°C. Plasma was removed and aliquoted into 250 μL portions. The plasma was frozen at −80°C until all samples were collected in order to isolate all EVs at the same time. 250 μL of human plasma was passed through size exclusion chromatography column to obtain eluent fractions containing EVs. The pooled fractions were filtered through a 100 kDa cut-off membrane (Thermo Fisher Scientific, Waltham, MA) and ultracentrifuged at 120,000 g for 2 hours at 4°C. The spin-down pellet containing EVs was resuspended in 400 μL of phosphate buffered saline (1xPBS) for downstream analysis.

Cryo-electronmicroscopy. Extracellular vesicles (3 μl) were applied onto 200-mesh copper grids (Quantifoil R1.2/1.3) that were glow discharged for 60 seconds. Excess solution was blotted with filter paper for...
chemiluminescence using ImageQuant LAS 400 phosphoimager. Proteintech, Illinois). Horseradish peroxidase coupled secondary antibodies were added and detected through β-actin (1:500, Santa Cruz Biotechnology, California), CD63 (1:1000, Santa Cruz Biotechnology, California), Cytochrome C (1:500, Santa Cruz Biotechnology, California), PLAP (1:200, Santa Cruz Biotechnology, California), Plac-1 (1:200, Proteintech, Illinois), and flotillin-1 (1:1000, Proteintech, Illinois). Horseradish peroxidase coupled secondary antibodies were used and detected through chemiluminescence using ImageQuant LAS 400 phosphoimager.

**Western blot analysis.** BeWo cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, Massachusetts). Cell lysates were used as a positive control and as tissue confirmation of the protein markers being assessed. Equal quantities of EV protein and cell lysate (10 μg) were run on polyacrylamide gels and then transferred onto nitrocellulose membranes (Life Technologies, New York). After blocking with 5% milk, membranes were probed with primary antibodies specific to the following proteins: syncytin-1, β-actin (1:200, Proteintech, Illinois), and flotillin-1 (1:1000, Proteintech, Illinois). Rabbit IgG, mouse IgG and goat IgG antibody quantum dot (Santa Cruz, California) were used as isotype controls. Each sample was run in duplicates and each experimental run was duplicated independently; the mean value of the two independent runs is represented. In each displayed panel, the nanoparticle size distribution curve is represented by particle size (nanometers) on the x-axis and nanoparticle concentration (x10⁶/ml) on the y-axis. The curve in blue represents total plasma EV pool distribution, and red curve represents the respective subpopulation.

**Nanoparticle detector analysis.** Isolated EVs from maternal plasma and BeWo cell line EVs were analyzed on the NanoSight NS300 nanoparticle detector light scatter mode (Malvern Instruments Inc., Massachusetts) for quantitation and size distribution of EVs. All captures were taken at a camera level of 16 with a detection threshold of 10. For STEV subpopulation analysis, EVs were studied for surface expression of syncytin-1, PLAP, and PLAC-1 using anti-human syncytin-1 (Santa Cruz Biotechnology, California), anti-PLAP (Santa Cruz Biotechnology, California) and anti-PLAC-1 (Santa Cruz Biotechnology, California) antibody conjugated quantum dots (Thermo Fisher Scientific, Massachusetts) on the nanoparticle detector fluorescence mode. Rabbit IgG, mouse IgG and goat IgG antibody quantum dot (Santa Cruz, California) were used as isotype controls. Each sample was run in duplicates and each experimental run was duplicated independently; the mean value of the two independent runs is represented. In each displayed panel, the nanoparticle size distribution curve is represented by particle size (nanometers) on the x-axis and nanoparticle concentration (x10⁶/ml) on the y-axis. The curve in blue represents total plasma EV pool distribution, and red curve represents the respective subpopulation.

**Statistical analysis.** First, data were checked for distribution. Comparative analysis for continuous variables (total EV concentration and STEV signal for Preeclampsia versus healthy pregnant control) were performed using independent sample t-test (2-tailed).

For receiver operating characteristic (ROC) curve, the true-positive rate (sensitivity) was plotted against the false-positive rate (specificity) to illustrate performance of a binary classifying system (Control versus Preeclampsia groups). A threshold was determined using the Youden index, and likelihood ratio, sensitivity and specificity were calculated. ROC curves were compared using the method of Delong et al. General statistics were assessed using StataMP version 14.2 (StataCorp LP, Texas), and scatter plots and NanoSight panels were constructed using Prism version 7.0 (GraphPad, California). All reported tests were 2-tailed and alpha level was set to 0.05.

**Table 1. Demographics and patient characteristics.**

|                          | Case (n = 21) | Control (n = 23) | P value |
|--------------------------|--------------|-----------------|---------|
| Maternal age – mean ± SD (years) | 29.7 ± 8.2   | 26.4 ± 5.1     | 0.12    |
| Race – n (%)             |              |                 |         |
| African American         | 19 (90.5)    | 20 (87.0)      | 0.71    |
| White                    | 2 (9.5)      | 3 (13.0)       |         |
| Body Mass Index - mean ± SD (kg/m²) | 31.2 ± 7.5  | 25.6 ± 6.2    | 0.01    |
| Gestational age at blood draw* - mean ± SD (weeks) | 31.3 ± 4.4  | 33.2 ± 4.0    | 0.63    |
| Parity – median [IQR]    | 0 [0–1]      | 1 [0–1]        | 0.46    |
| Tobacco use – n (%)      | 0 (0)        | 2 (8.7)        | 0.43    |
| Chronic HTN – n (%)      | 12 (57.1)    | 1 (4.3)        | 0.02    |
| Postnatal outcomes^      |              |                 |         |
| Gestational age at delivery – median [IQR] (weeks) | 32 [29–36]  | 39 [38–40]    | P < 0.001 |
| Birth weight (g) - mean ± SD | 1720 ± 593  | 3343 ± 641    | P < 0.001 |

*Equates to the gestational age of onset of preeclampsia for the cases. ^By definition, all cases were delivered preterm.

5.5 Sec using Vitrobot Mark IV (FEI Netherlands) at 4°C and the grids were immediately flash frozen by rapidly plunging the grid into liquid ethane at −165°C. CryoEM data for the sample was collected on a FEI Tecnai F 200 keV TEM microscope operated at 200 keV. Images were recorded on Falcon III direct electron detector at a magnification of 25,000x. The CryoEM micrograph was generated by averaging individual dose fractionated frames collected at a rate of 40 frames/second for 4 second exposures. The frames were motion corrected and summed into a single micrograph.
Results
EVs released by BeWo cells express placenta specific proteins. EV fraction obtained from BeWo culture supernatant was confirmed by Western blot for expression of canonical exosomal markers CD63 and flotillin-1, suggesting that EVs isolated utilizing methodology detailed yielded nanoparticles. There was no contamination from cellular debris and apoptotic bodies in EV fractions (cytochrome C). BeWo EVs showed high expression of placental proteins syncytin-1 and PLAP, but not of PLAC-1. The blots were cropped from different gels. Nanoparticle scatter analysis of BeWo EV preparations showed similar size distribution, with majority of EVs in the size range of 50–100 nm along with lower concentrations of microvesicles of larger sizes. NanoSight nanoparticle detector analysis for surface expression of placental proteins is shown. Higher abundance of placenta-specific markers syncytin-1 and PLAP was noted compared to PLAC-1, which was not elevated compared to IgG isotype background fluorescence. EV subpopulations positive for syncytin-1, PLAP, and PLAC-1 (red) are shown in relation to the total EV pool (blue). Appropriate IgG isotypes (mouse IgG, rabbit IgG) were used as negative controls.

Patient clinical data. Demographics, clinical parameters, and neonatal data are shown in Table 1. Subjects with preeclampsia were older (29.7 ± 8.2 years versus 26.4 ± 5.1 years; p = 0.12) and had higher body mass index (31.2 ± 7.5 kg/m² versus 25.6 ± 6.2 kg/m²; p = 0.01).
Maternal plasma EV analysis. First, morphology and size of the EVs were examined by cryo electron microscopy (Fig. 2A). Next, we confirmed that the EVs isolated using the methodology detailed expressed canonical exosome markers CD63 and flotillin-1 (Fig. 2B), with minimal contamination from cellular debris and apoptotic bodies (cytochrome C). The blots were cropped from different parts of the same gel. (C) Nanoparticle scatter analysis confirmed that majority of isolated EVs had size distribution consistent with exosomes (50–100 nm), and there was no difference in the size distribution of EVs between the Preeclampsia versus Control groups (p = 0.415). (D) Total plasma EV quantities in Preeclampsia versus Control groups were also similar (p = 0.313).

Next, we assessed whether differential protein expression in the plasma EV pool observed translates to differences at the mRNA level. We observed a much more heterogeneous syncytin-1 mRNA expression compared to the protein level (Fig. 3C), and differential syncytin-1 protein expression could not be extrapolated to the mRNA level. Taken together, these data demonstrated that syncytin-1 protein expression is upregulated in the plasma EV pool during pregnancy, and preeclampsia leads to changes in its expression at the protein level, but possibly not at the mRNA level. Given the specificity of syncytin-1 expression in placental trophoblasts, these data suggest that preeclampsia is associated with decreased production or increased clearance of EVs released by syncytiotrophoblasts into maternal plasma.

Quantitative analysis of syncytiotrophoblast EVs. Although total EV levels were indifferent between groups, Western blot analyses suggested that decreased levels of syncytin-1 expressing syncytiotrophoblast EVs are seen with preeclampsia. Therefore, we quantified the syncytiotrophoblast EVs on the nanoparticle detector.
using anti-syncytin-1 antibody conjugated quantum dots. This demonstrated that Preeclampsia subjects had lower levels of syncytin-1 expressing EVs compared to control subjects (Fig. 4A). Syncytin-1 EV quantitative signal was significantly lower in the Preeclampsia group (Fig. 4B) in accordance to the Western blot findings. Given this difference, we generated a receiver operating characteristic curve to understand the diagnostic potential of syncytin-1 EV signal to distinguish between preeclampsia versus normal pregnancy. This demonstrated an area under the curve of 0.975 ± 0.020. Syncytin-1 EV signal threshold level of <0.316 predicted preeclampsia in this cohort with 95.2% sensitivity and 95.6% specificity (Fig. 4C). However, total plasma EV numbers and mean plasma EV size had lower accuracy profiles to predict preeclampsia (Fig. 4C). Calculated thresholds along with sensitivity and specificity are represented (Table 2). Threshold was selected using maximum likelihood ratio, and the corresponding row is bolded. Also, a separate summary table is provided highlighting threshold as selected by maximum likelihood ratio, ROC-AUC, p value, sensitivity, specificity, PPV, NPV and numbers of patients and controls, respectively. Collectively, this data suggests that quantitative syncytio-trophoblast EV profiling, but not whole plasma EV profiling, might serve as a noninvasive diagnostic in conditions of placental pathology such as preeclampsia.

Discussion
Preeclampsia is one of the most common pregnancy-associated disorders, with increased morbidity and mortality risk rendered to the mother and the fetus. The diagnosis of this condition is based on clinical factors and typically occurs during the second trimester of pregnancy, but studies suggest that the mechanisms underlying the pathophysiology of preeclampsia are initiated early during the first trimester. Currently, there are no biomarkers for accurate and early diagnosis and monitoring of preeclampsia. Early diagnosis would enable closer monitoring and treatment of this condition, and may open the window for earlier intervention that might help reduce the associated risks to the fetus and the mother. In addition to investigations studying circulating free proteins and microRNAs for their biomarker potential, plasma extracellular vesicles, including exosomes, have been extensively studied in many medical fields for their diagnostic potential.

Circulating EVs quantitative and cargo profiles are dynamic and may reflect condition-specific changes mediated upon their tissue of origin. In support of this concept, we recently showed that in the setting of cell/organ transplantation, donor tissue specific exosome profiles accurately reflect injury inflicted from immunologic rejection on the transplant tissue in a time-specific manner. These investigations led us to propose that placental pathology/ injury contributing to onset of preeclampsia during pregnancy might also lead to marked changes in placental tissue-specific EV profiles in maternal plasma. We report our initial investigation of this concept.
The findings of our investigation support the growing body of literature that pregnancy renders an altered EV profile status in the maternal plasma and that the fetal-derived syncytiotrophoblasts release EVs into the maternal plasma. Furthermore, conditions associated with placental pathology such as preeclampsia lead to differences in total EV quantities in maternal plasma, and more importantly significant changes in syncytiotrophoblast specific EVs may be observed. In the two study cohorts, we noted a trend towards increasing total EV quantities in maternal plasma with preeclampsia. A recent study by Salomon et al. showed that increasing EV quantities are noted during latter stages of gestation, and furthermore, significantly higher number of EVs were seen in preeclampsia subjects at each gestational stage (early: 11–14 weeks, mid: 22–28 weeks, late: 32–38 weeks). Analysis of plasma EV protein content for PLAP by enzyme linked immunoabsorbent assay showed that significantly higher PLAP content was seen in preeclampsia subjects overall. In gestation matched samples, however, when the PLAP content was normalized to total plasma EV quantity, the difference in PLAP content between preeclampsia and control subjects was diminished. For early gestational stage samples, the positive and negative predictive values by receiver operating characteristic curve for exosomal PLAP content was 75% and 76% respectively in this study.

In another study analyzing third trimester maternal plasma EV samples comparing preeclampsia subjects to normotensive, total plasma EV quantities were significantly increased in preeclampsia subjects, with much higher fold differences in total plasma EV concentrations than that reported by Salomon et al. In early onset preeclampsia subjects compared to normotensive subjects <33-week gestation, 14.3-fold difference was seen in total plasma EV concentrations. In our investigation, we did not find such a big difference in total plasma EV numbers between normal and preeclampsia subjects, although our analysis was performed in plasma samples from pregnant females in 2nd or 3rd trimester of gestation. Our findings are more in accordance with Salomon et al., where there was <2-fold difference in total EV numbers between the two cohorts, with higher numbers seen in preeclampsia subjects. Pillay et al., also studied PLAP protein content in plasma EV fraction, and found

Figure 4. Decreased syncytin-1 EV signal in maternal circulation enables diagnosis of preeclampsia with high accuracy. (A) Syncytiotrophoblast EVs were quantified on the nanoparticle detector using anti-syncytin-1 antibody conjugated quantum dots. This demonstrated that preeclampsia subjects had lower levels of syncytin-1 expressing EVs compared to control subjects. NanoSight panels show syncytin-1 positive EV subpopulation (red) in relation to total plasma EV pool (blue). (B) Scatter plot analysis of STEV signal showed significantly decreased syncytin-1 signal in preeclampsia subjects \( p = 2.82 \times 10^{-11} \). (C) Receiver operating characteristic curve (ROC) in a binary cohort of preeclampsia versus control subjects was constructed for syncytin-1 EV signal, total plasma EVs quantity, and mean plasma EV size. This demonstrated an area under the curve of 0.975 ± 0.020 for STEV quantitative profiling, and a syncytin-1 EV signal threshold level of <0.316 predicted preeclampsia in this cohort with 95.2% sensitivity and 95.6% specificity. Total plasma EV numbers and mean plasma EV size had low diagnostic accuracy compared to STEV signal quantitation.
increasing total PLAP content with early onset preeclampsia but not late onset preeclampsia. But when normalized to plasma EV quantities, the PLAP content to EV quantity ratio showed significantly decreased values in late onset preeclampsia subjects compared to normotensive controls. Both these studies utilized plasma PLAP protein content as a marker of placental EVs and did not directly measure PLAP surface expression on EVs. These studies suggest that preeclampsia is associated with a state of increased total EV quantities in maternal plasma but not necessarily increased syncytiotrophoblast EVs. Also, increased circulating quantity of placental markers such as PLAP might not necessarily translate to increased syncytiotrophoblast specific EV concentration in maternal plasma.

| Threshold | Sensitivity% | 95% CI | Specificity% | 95% CI | Likelihood ratio |
|-----------|--------------|--------|--------------|--------|-----------------|
| <0.008    | 4.762        | 0.120% to 23.816% | 100       | 85.181% to 100% |
| <0.029    | 9.524        | 1.175% to 30.377% | 100       | 85.181% to 100% |
| <0.055    | 14.286       | 3.049% to 36.342% | 100       | 85.181% to 100% |
| <0.080    | 19.048       | 5.446% to 41.907% | 100       | 85.181% to 100% |
| <0.092    | 23.810       | 8.218% to 47.166% | 100       | 85.181% to 100% |
| <0.098    | 28.571       | 11.281% to 52.175% | 100      | 85.181% to 100% |
| <0.102    | 33.333       | 14.588% to 56.968% | 100       | 85.181% to 100% |
| <0.116    | 38.095       | 18.107% to 61.565% | 100       | 85.181% to 100% |
| <0.130    | 42.857       | 21.820% to 65.979% | 100       | 85.181% to 100% |
| <0.132    | 47.619       | 25.713% to 70.219% | 100       | 85.181% to 100% |
| <0.134    | 52.381       | 29.781% to 74.287% | 100       | 85.181% to 100% |
| <0.137    | 57.143       | 34.021% to 78.180% | 100       | 85.181% to 100% |
| <0.140    | 61.905       | 38.435% to 81.893% | 100       | 85.181% to 100% |
| <0.152    | 66.667       | 43.032% to 85.412% | 100       | 85.181% to 100% |
| <0.165    | 71.429       | 47.825% to 88.719% | 100       | 85.181% to 100% |
| <0.177    | 71.429       | 47.825% to 88.719% | 95.652    | 85.181% to 100% |
| <0.194    | 76.190       | 52.834% to 91.782% | 95.652    | 85.181% to 100% |
| <0.221    | 80.952       | 58.093% to 94.554% | 95.652    | 85.181% to 100% |
| <0.267    | 85.714       | 63.658% to 96.951% | 95.652    | 85.181% to 100% |
| <0.305    | 90.476       | 69.623% to 98.825% | 95.652    | 85.181% to 100% |
| <0.316    | 95.238       | 76.184% to 99.880% | 95.652    | 85.181% to 100% |
| <0.333    | 95.238       | 76.184% to 99.880% | 91.304    | 85.181% to 100% |
| <0.355    | 95.238       | 76.184% to 99.880% | 69.565    | 85.181% to 100% |
| <0.361    | 95.238       | 76.184% to 99.880% | 62.609    | 85.181% to 100% |
| <0.364    | 95.238       | 76.184% to 99.880% | 58.261    | 85.181% to 100% |
| <0.375    | 95.238       | 76.184% to 99.880% | 73.913    | 85.181% to 100% |
| <0.404    | 95.238       | 76.184% to 99.880% | 69.565    | 85.181% to 100% |
| <0.455    | 100          | 83.890% to 100%   | 69.565    | 85.181% to 100% |
| <0.488    | 100          | 83.890% to 100%   | 65.217    | 85.181% to 100% |
| <0.491    | 100          | 83.890% to 100%   | 60.870    | 85.181% to 100% |
| <0.496    | 100          | 83.890% to 100%   | 56.522    | 85.181% to 100% |
| <0.505    | 100          | 83.890% to 100%   | 52.174    | 85.181% to 100% |
| <0.543    | 100          | 83.890% to 100%   | 47.826    | 85.181% to 100% |
| <0.575    | 100          | 83.890% to 100%   | 43.478    | 85.181% to 100% |
| <0.588    | 100          | 83.890% to 100%   | 39.130    | 85.181% to 100% |
| <0.624    | 100          | 83.890% to 100%   | 34.783    | 85.181% to 100% |
| <0.650    | 100          | 83.890% to 100%   | 30.435    | 85.181% to 100% |
| <0.682    | 100          | 83.890% to 100%   | 26.087    | 85.181% to 100% |
| <0.714    | 100          | 83.890% to 100%   | 21.739    | 85.181% to 100% |
| <0.720    | 100          | 83.890% to 100%   | 17.391    | 85.181% to 100% |
| <0.734    | 100          | 83.890% to 100%   | 13.043    | 85.181% to 100% |
| <0.760    | 100          | 83.890% to 100%   | 8.696     | 85.181% to 100% |
| <0.797    | 100          | 83.890% to 100%   | 4.348     | 85.181% to 100% |
| <0.316    | 0.975        | <0.001% to 95.2%  | 95.7%     | 95.6%     | n = 21          |
| <0.242    | 0.970        | <0.001% to 95.2%  | 95.7%     | 95.6%     | n = 23          |

Table 2. Youden's Index for the performance of the STEV platform in predicting preeclampsia in the presented cohort. STEV signal threshold cut-off of <0.316 was 95.2% sensitive and 95.6% specific for diagnosis of preeclampsia.
In support of the above idea, Tannetta et al.\textsuperscript{51} studied microvesicles released by perfused placentas in an \textit{in vitro} closed-circuit system obtained by cesarean section from normal versus preeclampsia subjects. Unlike other studies that analyzed PLAP protein content by enzyme linked immunosorbent assay as a surrogate for placenta specific EVs, this study measured surface expression of PLAP on microvesicles. In flow cytometry analysis of microvesicles in the 300 nm to 1 μm range, they noted decreased percentage of PLAP positive microvesicles in perfused placentas from preeclampsia subjects compared to normal controls. In addition, mean fluorescence intensity for PLAP by flow cytometry was also decreased in microvesicles from preeclampsia subjects, suggesting that PLAP expressing EV quantity and the amount of PLAP carried on each microvesicle surface was decreased in microvesicles released by placentas from preeclampsia subjects. Accordingly, densitometry analysis of microvesicle protein content by Western blot for PLAP was significantly decreased in preeclampsia samples compared to normal controls. Furthermore, size distribution analysis of microvesicles by nanoparticle detector analysis, which enables analysis of particles in 10 nm to 1000 nm range, showed that placenta microvesicles subjects contained fewer microvesicles in the exosome size range compared to placenta from normal subjects. Taken together, these results suggest that perfused placentas from preeclampsia subjects release decreased PLAP positive microvesicles, with lower PLAP surface expression per microvesicle and decreased microvesicles in the exosome range. Therefore, placental pathology associated with preeclampsia might manifest as a decrease in EV production with decreased expression of placenta specific marker on syncytotrophoblast microvesicles, especially exosomes. The results of our investigation support these findings observed in a placenta perfusion model. Even though we found a general trend towards higher numbers of EVs in preeclampsia subjects, we noted that there was a significant reduction in syncytotrophoblast specific EV signal in preeclampsia maternal plasma samples. This decrease in syncytotrophoblast specific EV signal might be a reflection of lower number of placenta specific EVs, lower amounts of placenta specific marker on EVs, or a combination of both. These findings are in accordance to our proposed concept that tissue injury leads to decreased production of tissue specific EVs, especially exosomes.

In addition to PLAP, which is the most studied protein as a placenta specific marker, syncytin-1 and syncytin-2 proteins have also been reported to be altered in placental tissues from preeclampsia subjects\textsuperscript{52,53}. Syncytin-1 and -2 are human endogenous retrovirus envelope proteins shown to play a critical role in trophoblast fusion, a process vital to formation of multinucleated syncytiotrophoblasts. Reduced expression of both syncytin-1 and syncytin-2 mRNA was shown in primary trophoblasts cultured from placentas of mothers with preeclampsia compared to normal controls. By Western blot analysis, decreased protein levels of syncytin-1 were noted in trophoblasts from subjects with severe preeclampsia, but a more pronounced difference in protein expression was noted with syncytin-2. The same group also analyzed EVs from maternal serum isolated using a polymer-based EV isolation kit. Densitometry analysis of serum EV protein content by Western blot showed no significant differences in syncytin-1 levels between control and preeclampsia samples, but syncytin-2 levels were significantly decreased in preeclampsia samples. These findings suggest that unlike PLAP, which has been shown to be increased in overall content in plasma EV fractions from preeclampsia subjects, placenta specific proteins syncytin-1 and syncytin-2 are decreased in the plasma extracellular vesicle pool of preeclampsia subjects.

It is important to note that decreased syncytin-1 EV signal in preeclampsia subjects detected by nanoparticle detector analysis may not necessarily mean that there is decreased production of EVs by syncytiotrophoblasts under this condition. It could very well be that in preeclampsia, the density of syncytin-1 surface expression on EVs is reduced, which could result in decreased syncytin-1 EV signal detection without a decrease in overall EV production by syncytiotrophoblasts. Accordingly, just because our group and others have found increased EV quantities in maternal plasma from preeclampsia subjects does not mean that these increased numbers are due to increased EV production by placental syncytiotrophoblasts. At this point, our findings and the current literature support that overall a higher number of EVs are detected in maternal plasma from preeclampsia subjects compared to normal pregnancy. Also, there is evidence that increasing numbers of EVs are seen in maternal plasma during early to late gestation. Therefore, interpretation of the diagnostic potential of syncytiotrophoblast EVs must be investigated taking into consideration changes in peripheral blood EV profiles in a gestation-specific and condition-specific manner. To this effect, it will be important to understand gestation-specific changes in STEVs during normal pregnancy, before understanding specific changes associated with preeclampsia. Limitation of these findings is that the results in the current study were not confirmed in another cohort study. Lastly, current literature on EVs in the obstetrics diagnostics space reflects studies utilizing different EV isolation techniques, and various methods of signal quantitation. To carefully understand the potential of plasma EVs profiling for noninvasive diagnosis of placental pathologies, it will be important to standardize these methodologies and quantitation assays so that internal and intergroup variability is minimized.

**Conclusion**

In summary, we performed a retrospective blinded analysis of maternal plasma EVs from gestation-matched subjects with preeclampsia versus normal pregnancy for characterization of syncytiotrophoblast-specific EV profiles. Utilizing placenta-specific protein, syncytin-1, as a surface marker on syncytiotrophoblast EVs, we found that syncytin-1 specific EV signal in maternal plasma is significantly decreased in subjects with preeclampsia. Further characterization of maternal plasma syncytin-1 specific EVs may enable the development of a noninvasive biomarker platform for diagnosis and monitoring of preeclampsia and other placental pathologies. Furthermore, characterization of circulating syncytiotrophoblast EV protein and nucleic acid cargoes may provide a mechanistic window into placental pathologies.

**Data availability**

All data generated or analyzed during this study are included in this published article.
References

1. Magee, L. A. et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J. Obset. Gynaecol. Can. 36, 575–576 (2014).

2. Tranquilli, A. L., Brown, M. A., Zeeman, G. G., Dekker, G. & Sibai, B. M. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 3, 44–47 (2013).

3. Tranquilli, A. L. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 4, 97–104 (2014).

4. Wallis, A. B., Saftlas, A. F., Hsia, J. & Atrash, H. K. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am. J. Hypertens. 21, 521–526 (2008).

5. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 183, S1–S22 (2000).

6. Bulletins–Obstetrics ACoP. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol, 99, 159–167 (2002).

7. Lindheimer, M. D., Taler, S. J. & Cunningham, F. G. Hypertension in pregnancy. J. Am. Soc. Hypertens. 4, 68–78 (2010).

8. Brosens, I. B., Robertson, W. B. & Dixon, H. G. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet. Gynecol. Annu. 1, 177–191 (1972).

9. Fukui, A. et al. Changes of NK cells in preeclampsia. Am. J. Reprod. Immunol. 67, 278–286 (2012).

10. George, E. M. & Granger, J. P. Recent insights into the pathophysiology of preeclampsia. Expert. Rev. Obstet. Gynecol. 5, 557–566 (2010).

11. LaMarca, B. D., Gilbert, J. & Granger, J. P. Recent progress toward the understanding of the pathophysiology of hypertension during pregnancy. Hypertension 51, 982–988 (2008).

12. Nelissen, E. C., van Montfoort, A. P., Dumoulin, J. C. & Evers, J. L. Epigenetics and the placenta. Hum. Reprod. Update 17, 397–417 (2011).

13. Pijnenborg, R., Vercruysse, L. & Hanssens, M. Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen. Hypertens. Pregnancy 27, 183–196 (2008).

14. Roberts, J. M. & Gammill, H. S. Preeclampsia: recent insights. Curr. Opin. Obstet. Gynecol. 21, 124–129 (2005).

15. Damsky, C. H. & Fisher, S. J. Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Curr. Opin. Cell Biol. 10, 660–666 (1998).

16. Mutter, W. P. & Karumanchi, S. A. Molecular mechanisms of preeclampsia. Microvasc. Res. 75, 1–8 (2008).

17. Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940–950 (2011).

18. Wang, A., Rana, S. & Karumanchi, S. A. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 24, 147–158 (2009).

19. Mitchell, M. D. et al. Placental exosomes in normal and complicated pregnancy. Am. J. Obstet. Gynecol. 213, S173–S181 (2015).

20. Germain, S. J., Sacks, G. P., Sooranna, S. R., Sargent, I. L. & Redman, C. W. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J. Immunol. 178, 9494–9506 (2007).

21. Sarker, S. et al. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J. Transl. Med. 12, 204 (2014).

22. Tannetta, D., Collett, G., Vatish, M., Redman, C. & Sargent, I. Syncytiotrophoblast derived extracellular vesicles - Circulating biopsies reflecting placental health. Placenta 52, 134–138 (2017a).

23. Tannetta, D., Masliukaite, I., Vatish, M., Redman, C. & Sargent, I. J. Syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia. J. Reprod. Immunol. 119, 98–106 (2017b).

24. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3, 26913 (2014).

25. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 545–555 (2007).

26. Cuffe, J. M., Holland, O., Salomon, C., Rice, G. E. & Perkins, A. V. Review: Placental derived biomarkers of pregnancy disorders. Placenta 54, 104–110 (2017).

27. Pillay, P., Maharaj, N., Moodley, J. & Mackraj, I. Placental exosomes and pre-eclampsia: Maternal circulating levels in normal pregnancies and, early and late onset pre-eclamptic pregnancies. Placenta 46, 18–25 (2016).

28. Salomon, C. et al. Placental exosomes as early biomarker of preeclampsia - Potential role of exosomal microRNAs across gestation. J Clin Endocrinol Metab (2017).

29. Salomon, C. & Rice, G. E. Role of Exosomes in Placental Homeostasis and Pregnancy Disorders. Prog. Mol. Biol. Transl. Sci. 145, 163–179 (2017).

30. Tan, K. H. et al. Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles. Am. J. Obstet. Gynecol. 211(380), e381–313 (2014).

31. Vargas, A. et al. Syncytin-2 plays an important role in the fusion of human trophoblast cells. J Mol. Biol. 392, 301–318 (2009).

32. Vargas, A. et al. Reduced expression of both syncytin 1 and syncytin 2 correlates with severity of preeclampsia. Reprod. Sci. 18, 1085–1091 (2011).

33. Vargas, A. et al. Syncytin proteins incorporated in placenta exosomes are important for cell uptake and show variation in abundance in serum exosomes from infants with preeclampsia. FASEB J. 28, 3703–3719 (2014).

34. Haberthuer, A. et al. Donor tissue-specific exosome profiling enables noninvasive monitoring of acute rejection in mouse allogeneic heart transplantation. J Thorac Cardiovasc Surg (2018).

35. Vallabhajosyula, P. et al. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin. Invest. 127, 1375–1391 (2017).

36. American College of O, Gynecologists, Task Force on Hypertension in P, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 122, 1122–1131 (2013).

37. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988).

38. Bersinger, N. A., Smarason, A. K., Muttukrishna, S., Groome, N. P. & Redman, C. W. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens. Pregnancy 22, 45–55 (2003).

39. Kalousova, M., Muravsk, A. & Zima, T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv. Clin. Chem. 63, 169–209 (2014).

40. Poon, L. C., Maiz, N., Valencia, C., Plasencia, W. & Nicolaides, K. H. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet. Gynecol. 33, 23–33 (2009).
41. Sung, K. U., Roh, J. A., Eoh, K. J. & Kim, E. H. Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study. *Obstet. Gynecol. Sci.* 60, 154–162 (2017).

42. Cozzi, V. et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. *Placenta* 33, 1039–1044 (2012).

43. Carty, D. M., Delles, C. & Dominiczak, A. F. Novel biomarkers for predicting preeclampsia. *Trends Cardiovasc. Med.* 18, 186–194 (2008).

44. Ree, P. H. et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. *Fetal Diagn. Ther.* 29, 280–286 (2011).

45. Teixeira, P. G. et al. Placental growth factor (PIGF) is a surrogate marker in preeclamptic hypertension. *Hypertens. Pregnancy* 27, 65–73 (2008).

46. Kesavaran, F. et al. The placental vascular endothelial growth factor polymorphisms and preeclampsia/preeclampsia severity. *Clin. Exp. Hypertens.* 39, 606–611 (2017).

47. Tache, V., LaCoursiere, D. Y., Saleemuddin, A. & Parast, M. M. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. *Hum. Pathol.* 42, 1283–1288 (2011).

48. Fu, G. et al. MicroRNA-376c impairs transforming growth factor-beta and nodal signaling to promote trophoblast cell proliferation and invasion. *Hypertension* 61, 864–872 (2013).

49. Jiang, L. et al. Elevated microRNA-520g in pre-eclampsia inhibits migration and invasion of trophoblasts. *Placenta* 51, 70–75 (2017).

50. Julich, H., Willms, A., Lukace-Kornek, V. & Kornek, M. Extracellular vesicle profiling and their use as potential disease specific biomarker. *Front. Immunol.* 5, 413 (2014).

51. Tannetta, D. S., Dragovic, R. A., Gardiner, C., Redman, C. W. & Sargent, I. L. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. *PLoS One* 8, e56754 (2013).

52. Knerr, I., Beinder, E. & Rascher, W. Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. *Am. J. Obstet. Gynecol.* 186, 210–213 (2002).

**Acknowledgements**

Financial Support: Institutional Funding Department of Surgery, University of Pennsylvania, Philadelphia, PA; The McCabe Fund of the University of Pennsylvania, and the Penn Presbyterian Harrison Fund.

**Author contributions**

Study concept and design, experimental design, manuscript preparation: P.V. Data acquisition: A.H., L.K., C.R., A.F. and S.M. Statistical analysis: A.H., R.H., S.R., P.Z. and J.H. Critical review of manuscript: S.P., N.S. and L.L. Samples provided by: L.L. and S.P.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to P.V.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2020